Retatrutide vs Semaglutide vs Tirzepatide: Dosage Comparison
Phase 2 dosing data compared across 1mg, 4mg, 8mg, and 12mg weekly protocols
Update History ▾
August 2, 2026: Reconciled the approval FAQ with the five public Phase 3 toplines and Lilly's planned Q1 2027 U.S. BLA filing.
July 15, 2026: Citation hygiene — replaced bare-homepage citation links with exact primary-source deep links (specific press releases, ClinicalTrials.gov records, and dated news articles). Anchor text and article copy unchanged.
July 10, 2026: Corrected completed ADA 2026 retatrutide milestones from future to past tense.
July 10, 2026: Freshness correction — changed completed ADA 2026 milestones from future to past tense and added Lilly’s quantified TRIUMPH-1 urinary-tract-infection rates.
May 25, 2026: Aligned visible freshness, meta dateModified, schema, FAQ status language, and routing to the retatrutide research hub. Status unchanged: retatrutide remains investigational with No U.S. application has yet been filed; Lilly plans a BLA filing in Q1 2027.
May 23, 2026: Integrated TRIUMPH-1 Phase 3 obesity readout — dose-by-dose efficacy (4 mg 19.0% / 9 mg 25.9% / 12 mg 28.3% at 80 weeks; 30.3% at 104 weeks in BMI ≥35 extension; 45.3% achieved ≥30% weight loss on 12 mg) and the Phase 3 discontinuation-due-to-AE curve (4.1% / 6.9% / 11.3% across 4 / 9 / 12 mg vs 4.9% placebo, dysesthesia up to 12.5% on 12 mg).
April 2026: Audit compliance review and formatting update
Initial publication
Retatrutide is a triple-agonist (GLP-1/GIP/GCGR) dosed 2–12 mg/week, semaglutide is a GLP-1 agonist dosed 0.25–2.4 mg/week, and tirzepatide is a dual-agonist (GLP-1/GIP) dosed 2.5–15 mg/week. All three are administered once weekly via subcutaneous injection. Retatrutide showed the highest weight reduction in clinical trials — 28.3% at 80 weeks on 12 mg in the pivotal TRIUMPH-1 Phase 3 obesity trial (May 21, 2026), rising to 30.3% at 104 weeks in the BMI ≥35 extension, with a clean dose curve of 4 mg 19.0% / 9 mg 25.9% / 12 mg 28.3% — compared to tirzepatide (22.5% in SURMOUNT-1) and semaglutide (16.9% in STEP 1). Cross-trial comparisons have inherent limitations due to differences in study populations, endpoints, and durations. For the retatrutide-only route through trials and approval status, use the retatrutide research hub. For UAE regulatory status and archived batch evidence, see Retatrutide UAE. For research use only.
Mechanism of Action Comparison
The three compounds compared in this analysis differ fundamentally in their receptor pharmacology. Understanding these mechanistic differences is essential for interpreting dosage requirements and clinical outcomes.
Retatrutide (LY-3437943) — Triple Agonist
Retatrutide is the first triple hormone receptor agonist to reach Phase 3 clinical development. It simultaneously activates three metabolic receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and the glucagon receptor (GCGR). The GLP-1 component suppresses appetite and slows gastric emptying. The GIP receptor agonism enhances insulin secretion and may buffer GLP-1-mediated gastrointestinal effects. The GCGR component increases hepatic energy expenditure and fat oxidation—a mechanism absent from both semaglutide and tirzepatide.[1]
Semaglutide (Ozempic/Wegovy) — Single GLP-1 Agonist
Semaglutide is a selective GLP-1 receptor agonist with a long half-life engineered through albumin binding and fatty acid acylation. It acts on a single receptor pathway—GLP-1—to reduce appetite, slow gastric emptying, and improve glycaemic control. Semaglutide has received FDA approval for type 2 diabetes (Ozempic, 0.5–2 mg) and chronic weight management (Wegovy, 2.4 mg).[3]
Tirzepatide (Mounjaro/Zepbound) — Dual GLP-1/GIP Agonist
Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors. The addition of GIP receptor activation enhances insulin sensitivity and may provide a complementary weight-reduction mechanism to GLP-1 agonism alone. Tirzepatide has received FDA approval for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).[2]
The key pharmacological distinction: retatrutide’s glucagon receptor component drives additional energy expenditure through hepatic fat oxidation—a mechanism not present in either semaglutide or tirzepatide. This triple-agonist approach is hypothesised to explain the higher weight-reduction outcomes observed in clinical trials. For a detailed comparison of semaglutide and other GLP-1 agents, see our semaglutide comparison analysis.
Dosage Range Comparison
The table below provides a side-by-side comparison of dosage parameters for all three compounds based on published clinical trial protocols and approved prescribing information.
| Parameter | Retatrutide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Starting Dose | 2 mg | 0.25 mg | 2.5 mg |
| Maximum Dose | 12 mg | 2.4 mg | 15 mg |
| Dose Increments | 2→4→6→9→12 mg | 0.25→0.5→1.0→1.7→2.4 mg | 2.5→5→7.5→10→12.5→15 mg |
| Escalation Interval | 4 weeks per step | 4 weeks per step | 4 weeks per step |
| Frequency | Once weekly | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection |
| Administration Device | Pre-filled pen (investigational) | Pre-filled pen (approved) | Pre-filled pen (approved) |
| Receptor Targets | GLP-1 + GIP + GCGR | GLP-1 | GLP-1 + GIP |
Note: Retatrutide dose levels reflect investigational TRIUMPH study arms; semaglutide and tirzepatide values reflect their approved labels. They are shown to compare study design, not to provide a regimen, conversion, or administration instruction.
Why escalation appears in the study designs
The cited trials and labels used staged dose escalation to evaluate tolerability. This article compares those study-design choices at a high level and intentionally omits week-by-week instructions.
Clinical Outcomes
The following table summarises the primary weight-reduction outcomes from the pivotal Phase 3 trials for each compound. These are the most commonly cited headline efficacy figures.
| Parameter | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Trial | TRIUMPH-1 (obesity, no T2D) | SURMOUNT-1 | STEP 1 |
| Mean Weight Reduction (max dose) | 28.3% at 80 wk; 30.3% at 104 wk in BMI ≥35 extension | 22.5% | 16.9% |
| Proportion at ≥30% weight loss (max dose) | 45.3% on 12 mg | Not reported as primary | Not reported as primary |
| Dose (Max Arm) | 12 mg | 15 mg | 2.4 mg |
| Trial Duration | 80 weeks (104 wk extension in BMI ≥35) | 72 weeks | 68 weeks |
| Population | Adults with obesity, no T2D | Adults with obesity | Adults with obesity |
| Phase | Phase 3 topline (May 21, 2026); detailed results presented at ADA in June 2026 | Phase 3 (published) | Phase 3 (published) |
| Mechanism | Triple (GLP-1/GIP/GCGR) | Dual (GLP-1/GIP) | Single (GLP-1) |
| Regulatory Status | Investigational; Lilly plans a U.S. BLA filing in Q1 2027 after completing the CMC package | FDA approved (Zepbound) | FDA approved (Wegovy) |
Cross-trial comparison limitations: These outcomes are from separate clinical trials with different study populations, baseline characteristics, trial durations, and statistical endpoints. Direct head-to-head comparisons would require a randomised controlled trial evaluating all three compounds simultaneously — no such trial has been conducted to date. Retatrutide TRIUMPH-1 topline released May 21, 2026; detailed-results presentation at the ADA Scientific Sessions in June 2026. TRIUMPH-2 and TRIUMPH-3 topline results were reported July 23, 2026.[1][4]
| Dose | Mean Weight Loss at 80 weeks | Notes |
|---|---|---|
| 4 mg | 19.0% | Lowest active arm |
| 9 mg | 25.9% | Mid arm |
| 12 mg | 28.3% | Pivotal arm; 30.3% at 104 weeks in BMI ≥35 extension; 45.3% achieved ≥30% weight loss |
Source: Eli Lilly TRIUMPH-1 topline disclosure, May 21, 2026. The TRIUMPH Phase 3 program escalates 2 → 4 → 6 → 9 → 12 mg, with 4 mg, 9 mg, and 12 mg as the target dose arms.
| Arm | Discontinuation Due to AE |
|---|---|
| Placebo | 4.9% |
| Retatrutide 4 mg | 4.1% |
| Retatrutide 9 mg | 6.9% |
| Retatrutide 12 mg | 11.3% |
Phase 3 also surfaced new adverse events not heavily emphasised in Phase 2: dysesthesia up to 12.5% on 12 mg and UTIs. Lilly quantified urinary tract infections at 7.5%, 8.8%, and 8.4% across the 4, 9, and 12 mg groups versus 5.3% on placebo.
Several factors make cross-trial weight-reduction comparisons imprecise:
- Trial duration: TRIUMPH-1 ran 80 weeks (with a 104-week BMI ≥35 extension), SURMOUNT-1 ran 72 weeks, and STEP 1 ran 68 weeks. Longer follow-up in TRIUMPH-1 is favourable to retatrutide’s reported figure
- Baseline BMI: Mean baseline BMI differed across trials, which affects the magnitude of percentage weight loss
- Concomitant interventions: Diet and exercise counselling protocols varied between trial programs
- Publication status: TRIUMPH-1 (May 21, 2026) and TRIUMPH-4 (December 2025) are topline only; detailed TRIUMPH-1 results were presented at the ADA Scientific Sessions in June 2026; a peer-reviewed full publication was not located in this sweep
Despite these caveats, the trend is consistent across Phase 2 and Phase 3 data: triple-agonist retatrutide produces numerically greater mean weight reduction than dual-agonist tirzepatide, which in turn produces greater mean weight reduction than single-agonist semaglutide. The magnitude of this difference is broadly consistent with the increasing number of receptor pathways engaged.
Which Compound Is Right for Your Research?
The choice between these three compounds in a research context depends on the specific study objectives, available infrastructure, and the regulatory landscape relevant to the research setting.
- For maximum weight-reduction data: Retatrutide’s triple-agonist mechanism has produced the highest weight-reduction figures of any incretin-based compound studied to date. Researchers focused on the upper bounds of pharmacological weight reduction may find retatrutide most relevant
- For established safety and efficacy data: Semaglutide and tirzepatide have both completed their full Phase 3 programs and received regulatory approval. Published long-term safety data, cardiovascular outcome trial results (SELECT for semaglutide), and real-world evidence are available for both
- For mechanism-of-action studies: Retatrutide’s glucagon receptor component enables research into GCGR-mediated energy expenditure, hepatic fat metabolism, and the interplay between three receptor pathways—questions that cannot be studied with single- or dual-agonist compounds
- For comparative studies: Researchers designing protocols that compare incretin-based therapies should account for differences in dose ranges, titration timelines, and the lack of standardised head-to-head trial data
Retatrutide remains an investigational compound not yet approved by any regulatory authority. All research involving retatrutide should be conducted under appropriate oversight and compliance frameworks. For a broader comparison that includes additional pipeline compounds, see our retatrutide vs tirzepatide vs CagriSema analysis.
July 23, 2026 TRIUMPH-2 and TRIUMPH-3 update
Eli Lilly reported topline results from two additional Phase 3 retatrutide trials on July 23, 2026. In TRIUMPH-2 (1,152 adults with obesity or overweight and type 2 diabetes; 80 weeks), the company reported mean weight reductions of 12.7% at 4 mg, 19.1% at 9 mg, and 20.8% at 12 mg, with A1C reductions up to 1.6 percentage points. In TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease; 80 weeks), mean weight reduction reached 21.6% at 9 mg and 22.6% at 12 mg versus 3.2% on placebo. These are company-reported topline findings, not a head-to-head comparison; full TRIUMPH-2 results are scheduled as a late-breaker at EASD in Milan on September 30, 2026, with TRIUMPH-3 to follow at a future meeting.
Lilly also stated that it plans a U.S. Biologics License Application in Q1 2027 after completing the chemistry, manufacturing, and controls package; the company's Q2 2026 report (August 5) states the clinical data package is complete to support global registrations in obesity, obstructive sleep apnea, and knee osteoarthritis pain. Retatrutide remains investigational and no application has yet been approved. Primary source: Eli Lilly, July 23, 2026.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340. doi:10.1056/NEJMoa2206038
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Eli Lilly and Company. Lilly’s retatrutide (LY-3437943) met primary endpoint in TRIUMPH-4 Phase 3 obesity trial. Press release, December 11, 2025. investor.lilly.com
- Eli Lilly. TRIUMPH Clinical Trial Program for Retatrutide — Phase 3 Design. ClinicalTrials.gov.
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information. FDA approved June 2021. accessdata.fda.gov
- Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered powerful weight loss in TRIUMPH-1 Phase 3 obesity trial. May 21, 2026. investor.lilly.com
- tctMD. Retatrutide Achieves Large Weight Decreases in Patients Without Diabetes: TRIUMPH-1. May 2026. tctmd.com
- AJMC. Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial. May 2026. ajmc.com